Clinical Trial Update: Infliximab to Treat Children With Juvenile Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating infliximab for juvenile idiopathic arthritis in children was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Juvenile Rheumatoid Arthritis | Phase 2 | Status: TERMINATED